Products

PrimeWire Prestige Plus

PrimeWire Prestige Plus

Related Content

Immunis, Inc. has announced that a partnership with Springbok Analytics to implement their MRI-based AI muscle analysis technology in its Phase 1/2a Clinical Trial, assessing the efficacy of its novel secretome therapeutic (IMMUNA) in targeting sarcopenia.
News | Radiology Business
Immunis Partners with Springbok Analytics on MRI-based AI Muscle Analysis Technology

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and Biology, sheds light on the significant lung damage caused by severe COVID-19.
News | Artificial Intelligence
Study Applying AI to CT Scans Unveils Lung Damage Severity in COVID-19 Patients

June 11, 2024 — A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and ...

Time June 11, 2024
arrow
Latest innovations in clinical cancer research discussed at American Society of Clinical Oncology (ASCO) Annual Meeting
News | Breast Imaging
Breakthroughs in Breast Cancer: Susan G. Komen(R) Scholars and Studies Highlighted at ASCO 2024

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
Latest innovations in clinical cancer research discussed at American Society of Clinical Oncology (ASCO) Annual Meeting
News | Radiopharmaceuticals and Tracers
Shine Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
RaySearch Laboratories AB announced the release of the latest version of RayCare
News | Oncology Information Management Systems (OIMS)
RaySearch releases RayCare 2024A

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
A new UCLA study found Unfold AI’s precise prediction of prostate margins significantly impacts the success of focal therapy treatments
News | Prostate Cancer
New Study Demonstrates Avenda Health’s Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
Prospective pilot research study is first of its kind to attempt to quantify the impact of playing, training, and rest over a professional basketball season on musculoskeletal health with a cohort of elite professional basketball players from multiple teams
News | Radiology Imaging
NBA, NBPA, and NGBPU Collaborate with GE HealthCare and MedStar Health on Musculoskeletal and Joint Health Study

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
CHLA team helps validate guidelines promoting safer pediatric emergency department CT scans
News | Pediatric Imaging
Validated Rules Help Prevent Overuse of CT Scans for Diagnosing Traumatic Head and Abdominal Injuries in Kids

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer
News | Proton Therapy
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now